Cargando…

Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board

OBJECTIVE: Li-Fraumeni syndrome (LFS) is a pan-cancer predisposition syndrome caused by germline pathogenic variants in the gene TP53. The interpretation of TP53 variants in clinical scenarios outside the classic LFS criteria may be challenging. Here, we report a patient affected by 2 primary cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Xavier, Camila B, Link, Rudinei, Abreu, Leonília, Bettoni, Fabiana, Marson, Fabiane, Galante, Pedro A F, Masotti, Cibele, Amano, Mariane T, de Molla, Vinicius, Camargo, Anamaria A, Asprino, Paula F, Sabbaga, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322129/
https://www.ncbi.nlm.nih.gov/pubmed/37159554
http://dx.doi.org/10.1093/oncolo/oyad105
_version_ 1785068688877027328
author Xavier, Camila B
Link, Rudinei
Abreu, Leonília
Bettoni, Fabiana
Marson, Fabiane
Galante, Pedro A F
Masotti, Cibele
Amano, Mariane T
de Molla, Vinicius
Camargo, Anamaria A
Asprino, Paula F
Sabbaga, Jorge
author_facet Xavier, Camila B
Link, Rudinei
Abreu, Leonília
Bettoni, Fabiana
Marson, Fabiane
Galante, Pedro A F
Masotti, Cibele
Amano, Mariane T
de Molla, Vinicius
Camargo, Anamaria A
Asprino, Paula F
Sabbaga, Jorge
author_sort Xavier, Camila B
collection PubMed
description OBJECTIVE: Li-Fraumeni syndrome (LFS) is a pan-cancer predisposition syndrome caused by germline pathogenic variants in the gene TP53. The interpretation of TP53 variants in clinical scenarios outside the classic LFS criteria may be challenging. Here, we report a patient affected by 2 primary cancers at later ages, who harbored a likely pathogenic TP53 at low allele frequency detected in a blood sample. METHODS: The Molecular Tumor Board committee at our institution revisited the case of a patient who was enrolled in a research protocol for the investigation of genetic conditions associated with neuroendocrine tumors. Clinical, familial, and molecular data were reviewed. The patient received germline testing using a next generation sequencing multi-gene panel and was incidentally found to harbor a TP53 likely pathogenic variant, with 22% of variant allele fraction. Additional samples, including a second blood sample, oral swab, and saliva, were collected for DNA analysis. A new TP53 sequencing round was performed with the attempt to distinguish between a true constitutional germline variant and a somatically acquired variant due to aberrant clonal expansion of bone marrow precursors. RESULTS: Patient’s personal and familial history of cancer did not meet classic nor Chompret LFS criteria. Environmental risk factors for cancer were identified, such as alcohol abuse and tobacco exposure. The TP53 variant initially found in the next-generation sequencing was confirmed by Sanger sequencing in the previous DNA sample extracted from blood for the first analysis and in a second blood sample collected 6 years later. The TP53 variant was not detected in the DNA extracted from the oral swab and saliva samples. CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.
format Online
Article
Text
id pubmed-10322129
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-103221292023-07-06 Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board Xavier, Camila B Link, Rudinei Abreu, Leonília Bettoni, Fabiana Marson, Fabiane Galante, Pedro A F Masotti, Cibele Amano, Mariane T de Molla, Vinicius Camargo, Anamaria A Asprino, Paula F Sabbaga, Jorge Oncologist Precision Medicine Clinic: Molecular Tumor Board OBJECTIVE: Li-Fraumeni syndrome (LFS) is a pan-cancer predisposition syndrome caused by germline pathogenic variants in the gene TP53. The interpretation of TP53 variants in clinical scenarios outside the classic LFS criteria may be challenging. Here, we report a patient affected by 2 primary cancers at later ages, who harbored a likely pathogenic TP53 at low allele frequency detected in a blood sample. METHODS: The Molecular Tumor Board committee at our institution revisited the case of a patient who was enrolled in a research protocol for the investigation of genetic conditions associated with neuroendocrine tumors. Clinical, familial, and molecular data were reviewed. The patient received germline testing using a next generation sequencing multi-gene panel and was incidentally found to harbor a TP53 likely pathogenic variant, with 22% of variant allele fraction. Additional samples, including a second blood sample, oral swab, and saliva, were collected for DNA analysis. A new TP53 sequencing round was performed with the attempt to distinguish between a true constitutional germline variant and a somatically acquired variant due to aberrant clonal expansion of bone marrow precursors. RESULTS: Patient’s personal and familial history of cancer did not meet classic nor Chompret LFS criteria. Environmental risk factors for cancer were identified, such as alcohol abuse and tobacco exposure. The TP53 variant initially found in the next-generation sequencing was confirmed by Sanger sequencing in the previous DNA sample extracted from blood for the first analysis and in a second blood sample collected 6 years later. The TP53 variant was not detected in the DNA extracted from the oral swab and saliva samples. CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution. Oxford University Press 2023-05-09 /pmc/articles/PMC10322129/ /pubmed/37159554 http://dx.doi.org/10.1093/oncolo/oyad105 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Precision Medicine Clinic: Molecular Tumor Board
Xavier, Camila B
Link, Rudinei
Abreu, Leonília
Bettoni, Fabiana
Marson, Fabiane
Galante, Pedro A F
Masotti, Cibele
Amano, Mariane T
de Molla, Vinicius
Camargo, Anamaria A
Asprino, Paula F
Sabbaga, Jorge
Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board
title Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board
title_full Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board
title_fullStr Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board
title_full_unstemmed Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board
title_short Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board
title_sort suspected germline tp53 variants and clonal hematopoiesis of indeterminate potential: lessons learned from a molecular tumor board
topic Precision Medicine Clinic: Molecular Tumor Board
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322129/
https://www.ncbi.nlm.nih.gov/pubmed/37159554
http://dx.doi.org/10.1093/oncolo/oyad105
work_keys_str_mv AT xaviercamilab suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard
AT linkrudinei suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard
AT abreuleonilia suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard
AT bettonifabiana suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard
AT marsonfabiane suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard
AT galantepedroaf suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard
AT masotticibele suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard
AT amanomarianet suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard
AT demollavinicius suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard
AT camargoanamariaa suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard
AT asprinopaulaf suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard
AT sabbagajorge suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard